Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery
Citations Over TimeTop 1% of 2013 papers
Abstract
Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history. In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends associated with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters. Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronologically and classified according to an association with a particular clinical indication. Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated. The presented qualitative conclusions in this article aim to promote innovative insights into drug development.
Related Papers
- → Chemistry of sulfoxides and related compounds. XXXIII. Stereochemistry of substitution at tetracoordinate hexavalent sulfur. Nucleophilic reactions at sulfur in sulfonimidoyl compounds(1971)46 cited
- → Conformation of diaryl sulphides with intramolecular sulphur(II)—oxygen interaction: an X-ray study of methyl 2-(4-nitrophenylthio)benzoate and 2-diazoacethyl-4′-nitrodiphenyl sulphide(1986)17 cited
- Challenging Food and Drug Administration interpretations of the Federal Food, Drug, and Cosmetic Act.(2003)
- → Chemistry of N,N‐Bis(silyloxy)enamines. Part 6. Reactions of N,N‐Bis(silyloxy)enamines with Sulfur‐Centered and Sulfur‐Stabilized Electrophiles.(2003)
- → Approval from the Food and Drug Administration for unapproved use of an approved drug or device.(1994)